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Mass transferA comprehensive mathematical model has been developed to study release behaviour of Active Pharmaceutical
Ingredients (API) from pharmaceutical solid dosage oral formulations. An analytical model was found in
Dynochem resources and a numerical model was developed using COMSOLMultiphysics software using compu-
tational fluid dynamics based on finite elementmethod in order to solvemass transfer equations. Onlymolecular
diffusion was considered in the model to predict mass transfer of API molecules through the porous matrix. The
model was developed in two steps; in the first step Dynochemwas used to fit the data and find the unknown pa-
rameters. Then, COMSOL Multiphysics was used for prediction of API concentration over time. The experimental
results were taken from the lab for release of Paracetamol from HPMC tablets, in order to validate the modelling
process. The result of the study showed that both modelling methods are relatively good predictors of experi-
mental values and that even models with limited complexity can serve this purpose well. The results can be
used as predictive tools for designing novel drug controlled release systems.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Most pharmaceuticals are formulated in solid oral form due to ease
of manufacturing, and administration. Controlled release dosage forms
are a mechanism for delivering active pharmaceutical ingredients
(APIs) from pharmaceutical drugs at a pre-determined rate. Controlling
the rate of release of API from a drug is of great importance to the phar-
maceutical industry and has a number of benefits [1,2]. It can help avoid
problems of overdosing and under-dosing, allow the drug to be deliv-
ered locally which results in high concentrations of the drug at the site
of action, and improve the therapeutic effects of a drug while using a
fraction of the dosage [3]. Traditional delivery systems had immediate
and uncontrolled release kinetics, which caused bursts of drug release
leading to high concentrations which crossed the toxic threshold and
then fell off below the minimum effective therapeutic concentration.
In a typical controlled release formulation, an initial burst of active phar-
maceutical ingredient (API) is released to reach the effective therapeutic
concentration and then a controlled release of drug is maintained to
keep the concentration at this level [4].
Controlled release techniques are applied to various dosage forms
for different routes of administration. Intramuscular and subcutaneous
injections for example, are routes of administration that have used the
development of salts and esters of the drug substances and the develop-
ment of viscous vehicles in order to control the release rate of API.. This is an open access article underTransdermal patches are another type of dosage formwhich are applied
to the skin to deliver a drug to the bloodstreamvia diffusion through the
skin. Transdermal patches use the samepolymer technology as oral dos-
age forms. Themost important elements are themembrane which con-
trols the rate and the properties of the drug in the reservoir [2].
Themost common route of administration in the pharmaceutical in-
dustry is oral administration. A variety ofmethods to control the release
rate of drug substance from oral dosage forms have developed through-
out the history of the field. Coating tablets as a means of controlling the
release rate of drugs was one of the earliest attempts to achieve this
goal. Coating materials such as keratin were used on tablets as early as
1893 [5]. Later, waxes were used to coat tablets [6] and today polymers
are regularly used for this purpose. Individual polymers or mixtures of
different polymers can be used as coating materials, if a mixture is
used then varying the ratio of one polymer to the other can vary the
rate of disintegration of the tablet [7,8]. Polymers can also be used to
formmatrix systems in pharmaceutical tablets. Depending on themate-
rial used these can be hydrophobic inertmatrices, lipidmatrices, hydro-
philic matrices or biodegradable matrices. In these systems the active
pharmaceutical ingredient is dispersed uniformly throughout a matrix
formed by the linking chains of the polymer molecules [9]. The release
profile is determined by the loading of the API dispersed in the system,
the nature of the components and the geometry of the device [3].
Diffusional mass transfer controlled dosage forms are themain focus
of this paper. There are two main categories of diffusion controlled sys-
tems including the polymermatrices and reservoir systems. Matrix sys-
tems are also known as monolithic systems, and they can be dividedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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categorization is based on the initial concentration of the API in thema-
trix [3,10]. A reservoir system consists of an outer membrane which
controls the release rate of the active ingredient from a reservoir in
the centre of the tablet. The release profile is determined by the diffu-
sion mass transfer through the membrane. Reservoir devices can also
be divided into two categories based on initial drug concentration;
non-constant activity sources and constant activity sources [3]. Another
controlled release oral dosage form is the osmotic pump system which
these systems use osmotic pressure to control the release of API from
the dosage form [11,12].
Matrix controlled release dosage forms have become the most pop-
ular for oral administration due to their simplicity, ease of manufactur-
ing and reproducibility. Another advantage is that the release rate from
matrices is unaffected by thin spots, pinholes or other defects which
cause major problems with reservoir systems [13]. Based on the mate-
rial used the matrix tablets can be hydrophilic or hydrophobic [14].
Many different polymers such as microcrystalline cellulose (MCC),
Kollidon, hydroxyl propylmethyl cellulose (HPMC), etc. are used to cre-
ate tablet matrices [15]. These polymers can play crucial role as excipi-
ent in drug release. The excipient has shown to influence drug release
from tablets by affecting the table disintegration as well as interaction
with API molecules [16,17]. HPMC, also known as hypromellose, is one
of the most commonly used hydrophilic polymers for this purpose
[18]. HPMC is a swellable, hydrophilic polymer. Its functional group sub-
stitution and chain length affect its permeability and solubility in water.
Its nontoxicity, ease of handling and compression, and simplicity of
manufacturingmake it an ideal choice of polymer for these applications
[13,19]. For these reasons and its availability HPMC was used as the
polymer choice for the current research study.
Paracetamol, also known as acetaminophen, is the active pharma-
ceutical ingredient used in this research. Paracetamol is a drug that is
commonly used to treat mild headache, other mild to moderate pains
such as toothache or backaches etc. or symptoms of colds and flu [20].
It is taken orally in tablet form. Paracetamol is an odourless, white crys-
talline powder. It is a BCS Class III compound. BCS – Biopharmaceutics
Classification System – is a system that classifies pharmaceutical drugs
based on their solubility and permeability [21]. Indeed, controlling re-
lease of Paracetamol is of great importance for its therapeutic efficacy.
Computer modelling of controlled release has become an important
field of study for the analysis and optimization of delivery systems.
There are a number of benefits for developing mathematical models
for this purpose. Firstly, developing amodel that ismechanistically real-
istic can help one understand how the delivery system operates. In ad-
dition to this, if the models are accurate it can help avoid time
consuming and expensive trial and error experimentation. There is a
gap however between in vitro and in vivo simulations. Modelling of
in vitro has become very popular since Takeru Higuchi [22] used an
equation in 1961 to predict the release of API fromointmentfilms. How-
ever, in-silico simulations applied to advanced drug delivery systems
in vivo is not as commonly used. This is due to the complex nature of
drug transport within the body and the lack of mathematical equations
to describe these phenomena [23].
The current study was used two different methods including
Dynochem and computational fluid dynamic (CFD) technique using
COMSOL Multiphysics package to investigate API controlled releases
from polymer matrices.
2. Phase equilibria
Solubility of active pharmaceutical ingredients in dissolution media
is an important consideration in the field of controlled release. The sol-
ubility of a substance depends on the thermodynamic properties of that
substance (solute) and the properties of the solute in which it is dis-
solved. It also depends on other parameters such as temperature, pH,
pressure and the presence of other chemicals [24].Solubility is the thermodynamic equilibrium between two phases,
typically between solid and liquid phases. If more solute is added after
equilibrium has been reached, the solution becomes supersaturated,
which is metastable. Solubility is often quoted in terms of concentration
(g.kg−1 solvent or mol.L−1) and is denoted CS, however it can also be
given as a mole or mass fraction. Data for the solubility of specific mate-
rials can be determined experimentally and found in literature or it can
be calculated using phase equilibria law.
Granberg and Rasmuson [25] found solubility of paracetamol in pure
solvents in 1999 providing the solubility data of paracetamol in 26 dif-
ferent pure solvents in the temperature range of−5 °C to 30 °C. The re-
sults showed that the significance of the effects of temperature on the
solubility of the compound. However, it is desirable to know the solubil-
ity of paracetamol at 37 °C, as this is approximately body temperature
and will therefore determine the equilibrium solubility in vivo. It was
found that the equilibrium solubility at 37 °C to be approximately
21.3 g/kg solvent [26].
Phase equilibria law can be used to calculate the solubility of the
solid as a mole fraction, xS, when the activity coefficient of the solid in
the solution is known. In a saturated solution the chemical potential of
the solute in the solid state is equal to the chemical potential of the sol-
ute in the solution. Therefore, the fugacity of the two phases is equal.
The following equation can be derived for the activity of the solid
[4,10,23,24,27]:





















where γs is the activity coefficient of the solid, ΔHmf is the enthalpy of fu-
sion of solid at the melting point, Tm. The term ΔCP is the difference in
heat capacities between the solid and liquid phases, this is often consid-
ered negligible and the following simplified equation is used [24,26]:












Tablets containing various concentrations of paracetamol and HPMC
were prepared using Gamlen D series tableting apparatus and associ-
ated Gamlen computer software. Paracetamol was selected as model
API due to its high solubility in water and ease of measuring concentra-
tions using UV–Vis. Five different concentrations of API were prepared;
40%, 50%, 60%, 70% and 80%. Tablets were all weighed to a mass of
100 mg. Six tablets of each concentration were prepared in the lab. For
each concentration a total 700 mg of API and excipient was weighed
out initially. This was to account for the six tablets and the waste asso-
ciated with the tableting process. For example, for the 40% paracetamol
tablets, 280mg of paracetamol wasmixedwith 420mg of HPMC excip-
ient, for the 80% tablets 560mg of paracetamol wasmixedwith 140mg
of excipient, etc. The mixed powder was separated out into six 100 mg
samples for tableting.
3.2. Dissolution
The dissolution tests were carried out using the Pharma Test PTWS
apparatus. The machine contains six water baths that are heated and
stirred simultaneously. The stirrers were attached to the stirring rods
and the water baths were filled with 900 ml of deionised water. They
were then heated to a temperature of 37.5 °C. For every dissolution
test one bath was kept free of any tablet but was filled with deionised
water. This was because once samples were taken from the other
baths the same amount of volume (5 ml) was added to maintain a
3J.P. Walsh et al. / Journal of Molecular Liquids 317 (2020) 113899constant sink condition. The timer on the apparatus was started when
the first tablet was dropped. Each tablet drop was staggered by 1 min.
This was to make the sampling process easier to manage. Three or
four tablets were tested every time the dissolution apparatus was
used. Samples were taken after 5, 10, 20, 30, 40, 50, 60 and 120 min.
Samples were taken using a syringe, they were then pushed through a
micro filter into a 5 ml centrifuge tube. Each sample was then placed
in a cuvette and tested for absorbance readings using the UV spectro-
photometer. Also, it should be noticed that a calibration curve was con-
structed to relate concentration of paracetamol in a sample to
absorbance of UV light. Concentrations of the samples usedwere chosen
based on the expected minimum and maximum concentrations of API
in the dissolution tests. The UV measurements were carried out at the
wavelength of 249 nm, and a calibration curve with R2 of 0.999 was
obtained.
4. Model development
The modelling of controlled release delivery systems requires a sys-
tematic approach. Firstly, the basic parameters and description of the
dosage form needs to be identified, so that the appropriate equations
can be selected. This involves identifyingwhatmass transport processes
determine the rate of release of API, and possiblymaking some assump-
tions. A number of mass transport processes and other factors influence
the release of active ingredients from polymer matrices. When the dos-
age form comes in contact with the dissolution media the first mass
transport process that takes place is the diffusion of media into the tab-
let. The next step is the dissolution of the active drug in the dissolution
media. Dissolved drug substance can then diffuse through the polymer
matrix. Undissolved drug is not available for diffusion, therefore the ini-
tial drug concentration and solubility properties alter the rate of release
in this step. Other factors that can affect the release rate includepolymer
swelling, matrix erosion and osmotic effects [10].
When several of thesemass transport processes occur in a sequence,
if one of them is much slower than the other steps then that process is
the rate determining step. This assumption is used to simplify themath-
ematical description of controlled release. The release from polymer
matrices are typically categorized in the three groups including non-
biodegradable matrices known as diffusion-controlled systems;
swellable polymermatrices (swelling-controlled systems) andmatrices
in which the polymer erodes and disintegrates (erosion-controlled sys-
tems) [4].
Diffusional mass transport is almost always involved in the release
process. It's typically the dominant step, it can also play a major role
along with polymer swelling or matrix erosion/degradation. For non-
biodegradablematrices, drug diffusion, driven by a concentration gradi-
ent is what controls the release process. This can be quantified by Fick's
first law of diffusion:
J ¼ −D dc
dx
ð3Þ
where J (mol.m−2 s−1) is the rate ofmass transfer per unit area (flux), D
(m2.s−1) is the diffusion coefficient (diffusivity) and C (mol. m−3) is the
concentration of the diffusing drug. x refers to the direction of diffusion.














where x, y and z (m) are spatial coordinates and t (s) is time. The diffu-
sivity, D (m2.s−1), is usually assumed constant. This is in fact the case for
purely diffusion controlled systems, however D (m2.s−1) can be time
and position dependant in systems where polymer swelling or matrix
erosion is present [10].For the cylindrical matrix systems, the following are the equations









































whereMt andM∞ are the cumulative amounts of drug released at time t
and infinite time, respectively. The equations are derived by solving
Fick's second law of diffusion for the relevant geometry. For monolithic
solutions, early and late time approximations of the equation can be de-
rived. The early time approximation is suitable when the ratio MtM∞ ≤0:6





















There are multiple mathematical methods that can be used when
modelling release kinetics from dosage forms. Siepmann et al. [27] ap-
plied three different types of mathematical model to quantify the re-
lease kinetics of theophylline from HPMC and lactose matrix tablets.
The first is a numerical model, which considers diffusion in axial and ra-
dial direction in a cylinder, and also taking into account limited drug sol-
ubility effects. The second is an analytical solution of Fick's second law
which also considers axial and radial mass transport, but neglects lim-
ited drug solubility effects. The third model is an early time approxima-
tion of the analytical solution, this considers only radial mass transfer
but neglects radial, and it also neglects limited drug solubility effects.
The numerical model solves the following differential equation, an al-

























where t is time, C is concentration, r z and θ are the radial, axial and an-
gular coordinates, respectfully, and D is the diffusivity. The symmetry
about the axial and radial planes is shown in Fig. 1 (right). As there is
no concentration gradient with respect to θ, the equation can be simpli-





















Mathematical modelling of the process was first performed using
Dynochem software (DC4, Scale-Up Systems Ltd.). The model was used
to fit the recorded data in order to calculate any unknown parameters,
and then to predict experimental values. The ability to fit data automat-
ically is not available in COMSOL software. A manual fitting could be
possible by continuously changing the diffusivity coefficient until the
resulting concentration gradient matched the recorded data, however
Fig. 1. Schematic presentation of a cylindrical tablet for mathematical analysis and meshed rectangles with different sizes.
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nificant reason for choosingDynochem to assistwith themodellingpro-
cess. The model was developed by Dynochem and based on a literature
[28] that used HPMC tablets.Fig. 2. The change in paracetamol concentration in the solution as a function of time for
different paracetamol content in the tablets.
Fig. 3. Effect of initial API concentration on the amount of diffusion coefficient.4.2. COMSOL modelling
A numerical model was developed using COMSOL Multiphysics 3.5
software in order to predict the release rate of the 20% tablets with
heights 2.15mm and 3.74mm. COMSOL uses a computational fluid dy-
namics method called finite elements to solve differential equations, in
this case it was used to solve Fick's second law of diffusion for a tablet
with cylindrical geometry.
As discussed previously, Fick's law can be solved in two dimensions
by assuming radial and axial symmetry of concentration of API within
the tablet. This is a reasonable assumption as the tabletmixturewas ho-
mogeneous before the matrix was formulated. The software calculates
the concentration gradient for one quadrant in the cross-section of the
cylindrical tablet i.e. the width of the rectangle (quadrant) is the radius
of the tablet and the height of the rectangle is half of the real height of
the tablet. The diffusivity coefficient used for the model was taken
from the Dynochem fit for 20% tablets.
In the COMSOL software interface, once the appropriate packagewas
loaded (Chemical Engineering Module – Mass Transport – Diffusion –
Transient Analysis) a rectangle was drawn with the dimensions of one
quadrant of the tablet. In the case of the 2.15 mm tablet, a rectangle of
3 × 10−3 × 1.075 × 10−3 m2 was drawn and for the other tablet the di-
mensions were 3 × 10−3× 1.87 × 10−3 m2. A mesh was applied to the
rectangles in order for the software to solve the equation and produce
a concentration gradient. The meshed geometry was shown in Fig. 1.
Boundary one (left side) was set as axial symmetry, boundary two (bot-
tom) was set to symmetry and boundaries three (top) and four (right
side) were considered concentration 0 mol.m−3.Fig. 4. The comparison of experimental datawithmodelling values (Dynochem)when the
height of tablet is 2.15 mm.
Fig. 5. The comparison of experimental datawithmodelling values (Dynochem)when the
height of tablet is 3.74 mm.
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5.1. Experimental
The change in paracetamol concentration in the solution as a func-
tion of time was shown in Fig. 2. The drug loading was varied from 20Fig. 6. API concentration distribution into 60%. The rate of release is at its highest at the beginningwhen the tab-
let first comes in contactwith the dissolutionmedium. This is due to the
high concentration gradient between the tablet and the water bath,
which is at a maximum at t = 0. As API is released from the tablet the
concentration gradient decreases, leading to a slowdown in the rate of
release the plot would plateau to a constant concentrationwhen the ex-
periments were carried out for a long enough time period. In addition,
as it can be seen, the paracetamol release rates fromHPMCmatrices sig-
nificantly increased with increasing initial paracetamol content. In-
creasing dissolution rate could be attributed to the reduction of HPMC
content in the tablet. The tabletwith 20%APIwas used for themodelling
purposes, as the excipient content is high, and erosion rate is negligible.
Indeed, constant boundary was considered for the simulations.5.2. Dynochem modelling
Dynochem software was firstly used for determination of paraceta-
mol diffusivity coefficient at different API concentration in the tablets.
The diffusivity values calculated in the model fitting and it was used
subsequently for validation of developed model in Dynochem software
as well as COMSOL. The diffusivity value of 3.26 × 10−5 mm2.s−1 was
used for the simulation. Fig. 3 shows the API diffusivities in thethe tablets at different time points.
Fig. 8. The comparison of experimental data with modelling values (COMSOL) when the
height of tablet is 3.74 mm.
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Dynochem software at different initial API content in the tablet. The
API diffusion coefficient was decreased with increasing the API concen-
tration from 20% to 50%. It is expected that with increasing API content
in the tablet the diffusion coefficient should be increased however it
was decreased because lower availability of the solution for deep region
as well as the limited solubility of paracetamol. It was proved that there
is concentration gradient in the tablet based on its distance from the
tablet surface (Fig. 6).
Once the simulations were performed, the model needed to be vali-
dated through comparing with the measured data. The model predic-
tions were compared with experimental data obtained on the tablet
containing 20% API at two different heights including 2.15 mm and
3.74 mm. Figs. 4 and 5 show API concentration plots comparing the
data predicted by the model and the experimental results recorded
from the dissolution tests at two different heights. As it can be seen,
there is great agreement between modelling values and experimental
data especially for the tablet with the height of 2.15 mm. These predic-
tions show the validity of the fitting and modelling process.
5.3. COMSOL modelling
Fig. 6 illustrates the concentration distribution of paracetamol in the
tablets at different time points when the height of tablet is 2.15 mm. It
was observed that increasing time from 0 min to 120 min resulted in
an increased solution penetration distance in the particles, and thus an
enhancement in API dissolution. The reduction in the API concentration
of the sub-surface close to the tablet surface is higher than the deep area
in the tablet. It could be because the solution has to penetrate into the
deep regions in order to dissolve the API and it makes the lower disso-
lution rate of the API placed in the deep regions. It is seen that some
API is left inside the tablet after 120 min indicating that API is not fully
released. Changing the tablet thickness as well as porosity can improve
the full release of API from tablet containing HPMC.
The COMSOL model results were also compared with experimental
data. The results are presented in Figs. 7 and 8, as observed, great agree-
ment between experimental and modelling values are obtained for one
tablet height and less accurate predictions for the other tablet height
which confirm the accuracy of developed dissolution model.
6. Conclusions
Computer modelling of the release rate of pharmaceutical drugs
from tablet dosage forms is a very effective tool, even using models
with limited complexity. The experimental work was conducted in
order to validate the developedmodel. It was concluded that increasing
initial API concentration in tablet could enhance the dissolution rate
based on the experimental results. The model in the DynochemFig. 7. The comparison of experimental data with modelling values (COMSOL) when the
height of tablet is 2.15 mm.software package used an analytical solution of Fick's law. The diffusiv-
ity calculated took into account any error by assumptions made by the
model. The diffusivity coefficient was then used in the numerical
model in COMSOL. Interestingly, each model predicted good results on
a different tablet height. The Dynochem model's prediction was supe-
rior for the tablets with height 2.15 mm and the COMSOL model pre-
dicted the results from the 2.15 mm tablets with higher accuracy.
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